ProfileGDS5678 / 1444619_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 68% 68% 71% 67% 70% 70% 69% 67% 68% 68% 67% 68% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2470469
GSM967853U87-EV human glioblastoma xenograft - Control 24.1247168
GSM967854U87-EV human glioblastoma xenograft - Control 34.1271468
GSM967855U87-EV human glioblastoma xenograft - Control 44.5235671
GSM967856U87-EV human glioblastoma xenograft - Control 54.0658367
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3567770
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3725570
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2190769
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0924467
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1338768
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1284268
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0724767
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1635668
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2562669